Abstract
Purpose
KML-001 (sodium metaarsenite) displaces hTERT from the nucleus and is synergistic with cisplatin. This phase I trial tested the tolerability, activity and pharmacology of this combination.
Methods
Patients with advanced solid tumors that were “platinum sensitive,” PS 0-1, normal renal and hepatic function were eligible. Treatment was with cisplatin 75 mg/m2 day 1 and KML-001 p.o. daily days 1–14 on a 21-day cycle. A standard 3 + 3 design was employed. Blood specimens for arsenic and platinum pharmacokinetics were obtained at 0, 1, 2, 3, 4, 5, 6, 24 h and days 8, 15 and 22.
Results
Eighteen patients (7 M, 11 F) were evaluable for the primary endpoint of toxicity. Patients were heavily pretreated for a variety of malignancies (mean number of prior regimens = 3). Sixteen had prior platinum therapy. The dose-limiting toxicity was prolongation of the QTc interval, seen in three patients in cohort 3 (20 mg) (two during cycle 1, one during cycle 2). A documented response was seen in a patient with heavily pretreated SCLC in cohort one. Several other patients had reduction in tumor burden. In addition to the dose-limiting toxicity of QTc prolongation, the most common toxicities observed were nausea and vomiting and cytopenias. Myelosuppression was primarily seen in patients who had undergone prior radiotherapy.
Conclusions
The combination of KML-001 and cisplatin was technically feasible and active. However, the occurrence of significant QTc prolongation led to discontinuation of the trial. This prolongation was likely a result of electrolyte abnormalities resulting from cisplatin superimposed on the known risks of arsenicals and QTc prolongation. Combinations with other platinum agents (e.g., carboplatin) should be considered. This is the first fully reported human trial of KML-001.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blackburn EH (2000) Telomere states and cell fates. Nature 408:53–56
Keith WN, Evans JTR, Glasspool RM (2001) Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 195:404–414
Feng J, Funk WD, Wang SS et al (1995) The RNA component of human telomerase. Science 269:1236–1241
Nakamura TM, Morin GB, Chapman KB et al (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955–959
Greider CW (1991) Chromosome first aid. Cell 67:645–647
Kim NW, Piatyszek MA, Prowse KR et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015
Burger AM, Bibby MC, Double JA (1997) Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as target for cancer chemotherapy. Br J Cancer 75:516–522
Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787–791
Soignet SL, Frankel SR, Douer D et al (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852–3860
Douer D, Tallman M (2005) Arsenic trioxide: a new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396–2410
Alamolhodaei NS, Shirani K, Karimi G (2015) Arsenic cardiotoxicity: an overview. Environ Toxicol Pharmacol 40:1005–1014
Berenson JR, Boccia R, Siegel D et al (2006) Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135:174–183
Phatak P, Dai F, Butler M, Nandakumar MP, Gutierrez PL, Edelman MJ, Hendriks H, Burger AM (2008) KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Clin Cancer Res 14:4593–4602
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55
Matoušek T, Hernández-Zavala A, Svoboda M, Langrová L, Adair BM, Drobná Z, Thomas DJ, Stýblo M, Dědina J (2008) Oxidation state specific generation of arsines from methylated arsenicals based on L-Cysteine treatment in buffered media for speciation analysis by hydride generation - automated cryotrapping - gas chromatography-atomic absorption spectrometry with the multiatomizer. Spectrochim Acta Part B At Spectrosc. 63:396–406
Colville H, Dzadony R, Kemp R et al (2010) In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. J Extra Corp Technol 42:75–79
Zhang B, Suer S, Livak F et al (2012) Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells. Mol Pharmacol 82:310–321
Yoon JS, Kim ES, Park BB et al (2015) Anti-leukemic effect of sodium metaarsenite (KML001) in acute myeloid leukemia with breaking-down the resistance of cytosine arabinoside. Int J Oncol 46:1953–1962
Moon CH, Lee SJ, Lee HY et al (2013) KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model. PLoS One 8:e53900
Woo SR, Ham Y, Kang W et al (2014) KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. Biomed Res Int 2014:747415
Yoon JS, Hwang DW, Kim ES et al (2016) Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin’s lymphoma: an in vitro and in vivo study. Invest New Drugs 34:1–14
Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57(6):756–763
Urien S, Brain E, Bugat R et al (2005) Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 55:55–60
Lara PN, Redman MW, Kelly K et al (2008) Disease control rate at 8 weeks predicts clinical benefit in advanced non-small cell lung cancer: results from southwest oncology group randomized trials. J Clin Oncol 26:463–467
Acknowledgments
This trial was supported by R21CA130349 and P30 CA134274, from the National Cancer Institute. This project used the UPCI Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) and was supported in part by award P30-CA47904.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s00280-016-3159-7.
Rights and permissions
About this article
Cite this article
Edelman, M.J., Lapidus, R., Feliciano, J. et al. Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharmacol 78, 959–967 (2016). https://doi.org/10.1007/s00280-016-3148-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-016-3148-x